New Data to Show Viral Cure Rates in the Most Difficult to Treat Hepatitis C Patients

Boehringer Ingelheim to present five abstracts at ILC^TM (EASL) including data on interferon-free treatment in genotype-1 patients and those with advanced disease

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S.A. only

Key data from Boehringer Ingelheim’s hepatitis C virus (HCV) clinical trial programme, HCVerso^TM, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities. These data are one of five abstracts from a range of new Boehringer Ingelheim HCV data that have been accepted for presentation at the International Liver Congress (ILC)^TM 2012, taking place 18^th – 22^nd April in Barcelona, Spain.

Boehringer Ingelheim’s accepted abstracts not included in EASL media activities can be accessed through the EASL website today, www.easl.eu. The Boehringer Ingelheim data included in EASL media activities will remain under embargo until the time of presentation on 21^st April. All Boehringer Ingelheim’s data presentations are listed below.

Collectively, these data underscore the company’s focus on finding answers to the challenges faced by HCV patients.

Selected for oral presentation and inclusion in official EASL press office activities:
Title	Lead author	Presentation details
SOUND-C2 interim results: SVR4 and SVR12 with an interferon-free regimen of BI 201335 and BI 207127 +/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection	S. Zeuzem	Oral abstract presentation Date: Sat, 21^st April Time: 8:30 – 8:45 a.m. CEST
Poster presentations – abstracts available online currently:
Title	Lead author	Presentation details
SOUND-C2 interim analysis: The efficacy and safety of the interferon-free combination of BI 201335 and BI 207127 in genotype-1 HCV patients with cirrhosis	V. Soriano	Late breaker poster#: 1420 Date: Thurs, 19^th April Time: 12:00-1:30 p.m. CEST
Characterization of HCV NS3 variants that emerged during virologic breakthrough and relapse from BI 201335 Phase 2 SILEN-C2 study in pegylated-interferon plus ribavirin treatment-experienced patients	G. Kukolj	Poster#: 1185 Date: Sat, 21^st April Time: 12:30 – 1:30 p.m. CEST
Impact of early response definitions on duration and outcome of treatment with BI 201335 plus pegylated-interferon plus ribavirin	M. Sulkowski	Poster#: 1209 Date: Sat 21^st April Time: 12:30 – 1:30 p.m. CEST
Preclinical characterization of the hepatitis C virus NS5B polymerase non-nucleoside inhibitor BI 207127	P. Beaulieu	Poster#: 822 Date: Fri, 20^th April Time: 12:30 – 2:00 p.m. CEST

Boehringer Ingelheim is continuing to support its aim of delivering a simpler HCV cure for all patients, including those toughest to treat through the company’s rigorous clinical trial programme; HCVerso^TM.

For more information on Boehringer Ingelheim’s HCV portfolio, please visit www.boehringer-ingelheim.com and follow the company on Twitter www.twitter.com/boehringer.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Within the company’s global research network, Virology is one of the seven R&D areas with focus on Hepatitis C.

In 2010, Boehringer Ingelheim posted net sales of while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.